We are currently using a commercially available PCR assay to perform RNA testing on serum, plasma, and urine samples from symptomatic individuals, with the appropriate travel history, who are within 14 days of onset of symptoms. In the coming weeks, assuming the clinical need persists, it is intended that we will also introduce a second (laboratory developed) PCR assay to facilitate local confirmatory testing. In the interim, we will issue preliminary reports, whilst also referring samples to the Rare & Imported Pathogens Laboratory, Public Health England, for confirmation.
